# Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer

> **NCT00279448** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 9779 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** exemestane
- **DRUG:** tamoxifen

## Key facts

- **NCT ID:** NCT00279448
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2008-11
- **Final completion:** 2009-06
- **Target enrollment:** 9779 (ACTUAL)
- **Last updated:** 2011-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00279448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00279448, "Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00279448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*